Shao-Lee Lin - 09 Jul 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CUE
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 19:32:15 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shao-Lee Lin

Key filing fact

Shao-Lee Lin filed Form 4 for Cue Biopharma, Inc. (CUE) on 10 Jul 2026.

Key facts

This page summarizes Shao-Lee Lin's Form 4 filing for Cue Biopharma, Inc. (CUE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jul 2026, 19:32.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001725092 Primary reporting owner

Lin Shao-Lee

Relationship: Chief Executive Officer, Director
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Shao-Lee Lin
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Award

Transaction value
Shares: +327,537
Change %: +100%
Price: $0.000000^*
Shares after: 655,074
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Common Stock

Award

Transaction value
Shares: +327,537
Change %
Price: $0.000000^*
Shares after: 327,537
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 327,537
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

Footnote F2

Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.